Positive News SentimentPositive News Neuronetics Stock Price, News & Analysis (NASDAQ:STIM) $1.89 -0.06 (-3.08%) (As of 12/6/2023 ET) Add Compare Share Share Today's Range$1.87▼$1.9950-Day Range$1.05▼$2.2152-Week Range$1.03▼$6.95Volume46,913 shsAverage Volume163,902 shsMarket Capitalization$54.68 millionP/E RatioN/ADividend YieldN/APrice Target$9.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Neuronetics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside402.6% Upside$9.50 Price TargetShort InterestBearish1.27% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.68Based on 2 Articles This WeekInsider TradingSelling Shares$3,443 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.13) to ($0.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.36 out of 5 starsMedical Sector221st out of 957 stocksSurgical & Medical Instruments Industry26th out of 78 stocks 3.5 Analyst's Opinion Consensus RatingNeuronetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.50, Neuronetics has a forecasted upside of 402.6% from its current price of $1.89.Amount of Analyst CoverageNeuronetics has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.27% of the outstanding shares of Neuronetics have been sold short.Short Interest Ratio / Days to CoverNeuronetics has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Neuronetics has recently increased by 0.88%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldNeuronetics does not currently pay a dividend.Dividend GrowthNeuronetics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for STIM. Previous Next 3.7 News and Social Media Coverage News SentimentNeuronetics has a news sentiment score of 1.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Neuronetics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for STIM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Neuronetics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neuronetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,443.00 in company stock.Percentage Held by InsidersOnly 5.20% of the stock of Neuronetics is held by insiders.Percentage Held by Institutions62.23% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Neuronetics are expected to grow in the coming year, from ($1.13) to ($0.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neuronetics is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neuronetics is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuronetics has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Neuronetics Stock (NASDAQ:STIM)Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.Read More STIM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STIM Stock News HeadlinesDecember 4, 2023 | finance.yahoo.comNeuroStar TMS Receives Expanded Regulatory Approval in JapanDecember 2, 2023 | finance.yahoo.comInvestors in Neuronetics (NASDAQ:STIM) from five years ago are still down 90%, even after 40% gain this past weekDecember 7, 2023 | Edge On The Street (Ad)Americans Now Favor Gold Over Stocks as an Investment VehicleAmericans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges. November 15, 2023 | finance.yahoo.comNeuronetics to Present at the 35th Annual Piper Sandler Healthcare ConferenceNovember 13, 2023 | finanznachrichten.deNeuronetics: NeuroStar Elevates Depression Treatment with Cutting-Edge Technology AdvancementsNovember 13, 2023 | finance.yahoo.comNeuroStar Elevates Depression Treatment with Cutting-Edge Technology AdvancementsNovember 10, 2023 | benzinga.comDeep Brain Stimulation Devices Market to Hit $2,508.5 Million by 2030, Rising at 9.8% CAGR | Coherent Market InsightsNovember 9, 2023 | markets.businessinsider.comPositive Q3 Results and Commercial Initiatives Drive Plovanic’s Buy Rating on Neuronetics (STIM)December 7, 2023 | Financial Alphas (Ad)Lithium Discovery So BIG You Can't Miss it, Even From SpaceWith the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!November 9, 2023 | finance.yahoo.comNeuronetics Announces Continued Momentum from Health Plans for TMS Therapy CoverageNovember 8, 2023 | finance.yahoo.comNeuronetics, Inc. (NASDAQ:STIM) Q3 2023 Earnings Call TranscriptNovember 7, 2023 | finance.yahoo.comNeuronetics Reports Third Quarter 2023 Financial and Operating ResultsNovember 7, 2023 | finance.yahoo.comNeuronetics Inc (STIM) Reports 8% Revenue Growth in Q3 2023October 24, 2023 | finance.yahoo.comNeuronetics to Report Third Quarter 2023 Financial and Operating Results and Host Conference CallOctober 16, 2023 | finance.yahoo.comBrain Stimulation Highlights Best Practices for Optimal TMS Treatment OutcomesOctober 3, 2023 | finance.yahoo.comNeuronetics Draws Down Remaining $22.5 Million Available Under Credit FacilitySeptember 21, 2023 | benzinga.comBoard Member of Neuronetics Purchased $51K In StockSeptember 12, 2023 | finance.yahoo.comIn Recognition of Suicide Prevention Month, NeuroStar Voices Portal Amplifies Stories of Real People Beating DepressionSeptember 6, 2023 | msn.comNeuronetics: Large Losses May Be Repelling InvestorsAugust 24, 2023 | 247wallst.comCannell Capital Now Owns 8.45% of NeuroneticsAugust 19, 2023 | finance.yahoo.comCannell Capital LLC Reduces Stake in Neuronetics IncAugust 14, 2023 | finance.yahoo.comNeuronetics Revolutionizes Patient Communication and Provider Support Through Its Exclusive TrakStar® PlatformAugust 11, 2023 | finance.yahoo.comNeuronetics (STIM) Upgraded to Buy: What Does It Mean for the Stock?August 9, 2023 | markets.businessinsider.comNeuronetics (STIM) Receives a Buy from JMP SecuritiesAugust 8, 2023 | finance.yahoo.comNeuronetics Reports Record Second Quarter 2023 Financial and Operating ResultsJuly 25, 2023 | finance.yahoo.comNeuronetics to Report Second Quarter 2023 Financial and Operating Results and Host Conference CallJuly 22, 2023 | ca.finance.yahoo.comSTIM - Neuronetics, Inc.See More Headlines Receive STIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/05/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:STIM CUSIPN/A CIK1227636 Webwww.neurostar.com Phone(610) 640-4202Fax610-640-4206Employees211Year FoundedN/APrice Target and Rating Average Stock Price Target$9.50 High Stock Price Target$12.00 Low Stock Price Target$7.00 Potential Upside/Downside+402.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,160,000.00 Net Margins-47.81% Pretax Margin-47.81% Return on Equity-70.12% Return on Assets-31.99% Debt Debt-to-Equity Ratio0.97 Current Ratio4.63 Quick Ratio4.00 Sales & Book Value Annual Sales$65.21 million Price / Sales0.84 Cash FlowN/A Price / Cash FlowN/A Book Value$2.10 per share Price / Book0.90Miscellaneous Outstanding Shares28,930,000Free Float27,428,000Market Cap$54.68 million OptionableNot Optionable Beta2.03 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Keith J. Sullivan (Age 65)President, CEO & Director Comp: $1.53MMr. Stephen J. Furlong M.S. (Age 59)Executive VP, CFO & Treasurer Comp: $787.87kMr. W. Andrew Macan (Age 50)Executive VP, GC, Chief Compliance Officer & Corporate Secretary Comp: $646.55kMr. Rusty PageSenior VP of Operations & QualityMs. Lisa Metzner-RosasSenior VP & Chief Marketing OfficerMs. Kara ThorntonSenior Vice President of Human ResourcesMs. Sara GrubbsSenior VP & Chief Revenue OfficerMr. Rick GrubbsSenior Vice President of National AccountsMr. Cory S. AndersonSenior Vice President of R&D and ClinicalMore ExecutivesKey CompetitorsPro-DexNASDAQ:PDEXInspireMDNYSE:NSPRCytosorbentsNASDAQ:CTSOCarmellNASDAQ:CTCXAlpha Healthcare Acquisition Corp. IIINASDAQ:ALPAView All CompetitorsInsiders & InstitutionsCannell Capital LLCBought 65,240 shares on 11/22/2023Ownership: 9.796%Kent Lake Capital LLCBought 1,622,938 shares on 11/15/2023Ownership: 8.051%Townsquare Capital LLCSold 49,544 shares on 11/15/2023Ownership: 0.096%Acadian Asset Management LLCSold 52,122 shares on 11/13/2023Ownership: 1.277%Millrace Asset Group Inc.Sold 153,345 shares on 11/13/2023Ownership: 0.822%View All Insider TransactionsView All Institutional Transactions STIM Stock Analysis - Frequently Asked Questions Should I buy or sell Neuronetics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STIM shares. View STIM analyst ratings or view top-rated stocks. What is Neuronetics' stock price target for 2024? 2 analysts have issued 1-year price objectives for Neuronetics' shares. Their STIM share price targets range from $7.00 to $12.00. On average, they anticipate the company's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 402.6% from the stock's current price. View analysts price targets for STIM or view top-rated stocks among Wall Street analysts. How have STIM shares performed in 2023? Neuronetics' stock was trading at $6.87 at the start of the year. Since then, STIM shares have decreased by 72.5% and is now trading at $1.89. View the best growth stocks for 2023 here. When is Neuronetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024. View our STIM earnings forecast. How were Neuronetics' earnings last quarter? Neuronetics, Inc. (NASDAQ:STIM) posted its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.03. The business earned $17.88 million during the quarter, compared to the consensus estimate of $17.66 million. Neuronetics had a negative trailing twelve-month return on equity of 70.12% and a negative net margin of 47.81%. What guidance has Neuronetics issued on next quarter's earnings? Neuronetics updated its fourth quarter 2023 earnings guidance on Tuesday, November, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $19.00 million-$21.00 million, compared to the consensus revenue estimate of $19.76 million. What other stocks do shareholders of Neuronetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST). When did Neuronetics IPO? (STIM) raised $75 million in an IPO on Thursday, June 28th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers. Who are Neuronetics' major shareholders? Neuronetics' stock is owned by many different institutional and retail investors. Top institutional investors include Cannell Capital LLC (9.80%), Kent Lake Capital LLC (8.05%), First Eagle Investment Management LLC (2.69%), Acadian Asset Management LLC (1.28%), Millrace Asset Group Inc. (0.82%) and Blair William & Co. IL (0.32%). Insiders that own company stock include Bruce Joseph Shook, Cannell Capital Llc, Gregory Harper, Keith J Sullivan, Paul Liberman, Robert Cascella, Sheryl L Conley, Stephen Furlong and William Andrew Macan. View institutional ownership trends. How do I buy shares of Neuronetics? Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:STIM) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuronetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.